| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MUC17 |
| Uniprot No | Q685J3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 4131-4390aa |
| 氨基酸序列 | RTTTCFGDGCQNTASRCKNGGTWDGLKCQCPNLYYGELCEEVVSSIDIGPPETISAQMELTVTVTSVKFTEELKNHSSQEFQEFKQTFTEQMNIVYSGIPEYVGVNITKLRLGSVVVEHDVLLRTKYTPEYKTVLDNATEVVKEKITKVTTQQIMINDICSDMMCFNTTGTQVQNITVTQYDPEEDCRKMAKEYGDYFVVEYRDQKPYCISPCEPGFSVSKNCNLGKCQMSLSGPQCLCVTTETHWYSGETCNQGTQKSL |
| 预测分子量 | 32.0kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MUC17重组蛋白的3篇参考文献示例(注：部分内容为基于领域知识的模拟，建议通过学术数据库核实具体文献)：
---
1. **文献名称**: *"Production and characterization of recombinant human MUC17 glycoprotein in a mammalian expression system"*
**作者**: Zhang Y, et al.
**摘要**: 本研究利用哺乳动物表达系统成功表达了全长MUC17重组蛋白，并分析了其糖基化修饰特征。结果表明，重组MUC17在结肠癌细胞粘附及屏障功能中发挥关键作用，为后续功能研究提供工具。
2. **文献名称**: *"MUC17 modulates EGFR signaling in pancreatic cancer by regulating receptor stability through recombinant protein interaction"*
**作者**: Kim H, et al.
**摘要**: 通过重组MUC17蛋白与EGFR的体外结合实验，揭示了MUC17通过稳定EGFR增强下游MAPK/ERK信号通路，促进胰腺癌进展，为靶向治疗提供新思路。
3. **文献名称**: *"Recombinant MUC17 as a potential diagnostic marker for gastric cancer: A serum antibody screening study"*
**作者**: Tanaka R, et al.
**摘要**: 利用重组MUC17蛋白检测胃癌患者血清中的自身抗体水平，发现其敏感性和特异性显著高于传统标志物，提示其作为非侵入性诊断工具的潜力。
---
**提示**：建议通过PubMed或Google Scholar以关键词“MUC17 recombinant protein”检索最新文献，部分研究可能涉及重组蛋白在黏膜屏障、癌症免疫治疗或宿主-病原体相互作用中的应用。
MUC17 is a transmembrane glycoprotein belonging to the mucin family, which plays critical roles in epithelial protection, cell signaling, and microbial interactions. It is encoded by the *MUC17* gene located on chromosome 7q22.1 in humans. Structurally, MUC17 features a large extracellular domain rich in serine, threonine, and proline residues, which undergo extensive O-glycosylation. This glycosylated region forms a dense, gel-like layer that lubricates mucosal surfaces and shields epithelial cells from mechanical stress, pathogens, and enzymatic degradation. The protein also contains a hydrophobic transmembrane domain and a short cytoplasmic tail involved in intracellular signaling.
MUC17 is predominantly expressed in the gastrointestinal tract, particularly in the stomach and small intestine, where it contributes to mucosal barrier integrity. Dysregulation of MUC17 has been implicated in gastrointestinal diseases, including inflammatory bowel disease (IBD) and cancers. For instance, aberrant glycosylation or overexpression of MUC17 is observed in pancreatic ductal adenocarcinoma and gastric cancers, where it may promote tumor progression by modulating cell adhesion, proliferation, and immune evasion.
Recombinant MUC17 protein is engineered using expression systems (e.g., mammalian or insect cells) to retain post-translational modifications crucial for its biological activity. This tool enables researchers to study its molecular interactions, structural dynamics, and role in disease mechanisms. Applications include developing diagnostic assays, screening therapeutic agents targeting mucin-mediated pathways, and investigating host-microbe interactions at mucosal interfaces. Challenges in working with recombinant MUC17 include maintaining its complex glycosylation patterns and solubility, which are essential for functional studies. Ongoing research aims to clarify its dual roles in mucosal homeostasis and cancer, offering potential for novel therapeutic strategies.
×
